

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
955-3P/CON

SERIAL NO.
09/780,953

APPLICANT
M. Suthanthiran, et
al.

CONFIRMATION NO.
1712

FILING DATE
February 9, 2001

GROUP 1642
Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Aut	5,147,799	9/15/92	Bursuker, et al.			RECEIVED
Aut	5,278,145	1/11/94	Keller, et al.			JAN 15 2002
Aut	5,426,098	6/20/95	Carlino			TC 1700
Aut	5,656,587	8/12/97	Sporn, et al.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Aut		B. Li, P. K. Sehajpal, A. Khanna, H. Vlassara, A. Cerami, K. H. Stenzel, and M. Suthanthiran, "Differential Regulation of Transforming Growth Factor β and Interleukin 2 Genes in Human T Cells: Demonstration by Usage of Novel Competitor DNA Constructs in the Quantitative Polymerase Chain Reaction," <i>J. Exp. Med.</i> (1991) <u>174</u> : 1259-1262
Aut		Ashwani Khanna, Baogui Li, Kurt H. Stenzel, and Manikkam Suthanthiran, "Regulation of New DNA Synthesis in Mammalian Cells by Cyclosporine," <i>Transplantation</i> (1994) <u>57</u> : 577-582
Aut		Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM, "Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz[a]-anthracene," <i>Cancer Res.</i> (1997) <u>57</u> : 5564-5570 (Abstract Only)


145847_1

EXAMINER

Anne L. Bellum DATE CONSIDERED

1/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.



TECH CENTER 1600/2900

RECEIVED
JAN 10 2002

FORM PTO-146 (01-02) DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 955-3P/CON	SERIAL NO. 09/780,953
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT M. Suthanthiran	CONFIRMATION NO. 1712
(Use several sheets if necessary)		FILING DATE February 9, 2001	GROUP 1642 Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Arlt	5,958,411	9/28/99	Logan et al.			
Ar H	5,824,655	10/20/98	Border			
Ar H	5,595,722	1/21/97	Grainger et al.			
Ar H	5,583,103	12/10/96	Ruosahti et al.			
Ar H	5,262,319	11/16/93	Iwata et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Ar H		1.	Hojo et al., "Cyclosporine Induces Cancer Progression by a Cell-autonomous Mechanism", <u>Nature</u> (1999), 397(6719): 530-534. (1999), <u>397: 471-472</u> .
		2.	Gary J. Nabel, "A Transformed View of Cyclosporine", <u>Nature</u> (1999), <u>397: 471-472</u> .
		3.	Carlos L. Arteaga et al. "Reversal of Tamoxifen Resistance of Human Breast Carcinomas <i>In Vivo</i> by Neutralizing Antibodies to Transforming Growth Factor- β ", <u>Journal of the National Cancer Institute</u> , (1999), 91(1): 46-53.


EXAMINER Anne L. Hollen DATE CONSIDERED 1/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

TECH CEN

JAN 10
2002

RECEIVED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
955-3P/CONSERIAL NO.
09/780,953APPLICANT
M. SuthanthiranCONFIRMATION NO.
1712FILING DATE
February 9, 2001GROUP
1647
Unassigned

Art 4

4. Wojtowicz-Praga et al. "Modulation of B16 Melanoma Growth and Metastasis by Anti-Transforming Growth Factor β Antibody and Interleukin-2", Journal of Immunotherapy (1996), 19: 169-175.

Art 4

5. Carlos L. Arteaga et al. "Anti-Transforming Growth Factor (TGF)- β Antibodies Inhibit Breast Cancer Cell Tumorigenicity and Increase Mouse Spleen Natural Killer Cell Activity, J. Clin. Invest. (1993), 92: 2569-2576.

Art 4

6. Magdalene Hoefer et al., "Anti-(transforming growth factor β) Antibodies with Predefined Specificity Inhibit Metastasis of Highly Tumorigenic Human Xenotransplants in nu/nu Mice", Cancer Immunol Immunother (1995), 41: 302-308.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

144543_1.DOC

EXAMINER

Anne L Holloman

DATE CONSIDERED

1/21/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.